BX471 is a potent and selective antagonist of the chemokine receptor CXCR3, which plays a key role in the recruitment of immune cells to sites of inflammation. It is primarily investigated for its anti-inflammatory properties, particularly in autoimmune and chronic inflammatory diseases. Research has explored its potential in conditions such as multiple sclerosis, rheumatoid arthritis, and psoriasis, where CXCR3-mediated T-cell migration contributes to tissue damage. By blocking CXCR3, BX471 reduces the infiltration of inflammatory cells into affected tissues, thereby modulating disease progression. It has also been studied in transplant rejection models, showing promise in prolonging graft survival by dampening the immune response. While still in preclinical and early research stages, BX471 serves as an important tool compound for understanding CXCR3 biology and developing targeted immunotherapies.